Imunocytochemistry analysis of HIF-1± and VEGF in strains of breast Cancer in response to genistein treatment

• Grant number: 12/15597-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: October 01, 2012
• End date: September 30, 2013
• Field of knowledge: Agronomical Sciences - Veterinary Medicine
• Principal Investigator: Debora Aparecida Pires de Campos Zuccari
• Grantee: Cinthia Takassi Moritsugu
• Host Institution: Faculdade de Medicina de São José do Rio Preto (FAMERP). Secretaria de Desenvolvimento Econômico (São Paulo - Estado). São José do Rio Preto , SP, Brazil

Abstract

The mammary neoplasias are the most common tumors in women being the main cause of death due to late diagnosis, reflected in tumor growth and metastasis development. The tumor growth requires the formation of new blood vessels, is stimulated by vascular endothelial growth factor (VEGF) expressed under the control of the transcription factor hypoxia-inducible (HIF-1±). VEGF, its receptors, and molecules involved in angiogenesis are major targets for new therapeutic agents. Some studies have shown that genistein, belonging to the family of isoflavones (polyphenols) has oncostáticos effects. For its properties anti-angiogenic, acting in the regulation of expression of pro-angiogenic factors by inhibiting the activity of protein tyrosine kinase. The objective of this study is to verify the expression of HIF-1± and VEGF by immunocytochemistry cell lines of breast cancer in response to induction of hypoxia and treatment with genistein. The results obtained in this study may provide potential benefits of the use of genistein as a therapeutic agent in the treatment of breast cancer, contributing to growth control and tumor invasion.(AU)